Travis Erickson
Family Medicine · Oak Harbor, WANPI 1952350431
Payments from drug & device makers
Across 86 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$264
- Lilly USA, LLC$256
- Amgen$142
- Pfizer$134
- Novartis$105
- AstraZeneca$104
- plus $434 from 14 others
What the payments were for
- Food & beverage$1,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $264 |
| Lilly USA, LLC | 18 | $256 |
| Amgen | 7 | $142 |
| Pfizer | 8 | $134 |
| Novartis | 6 | $105 |
| AstraZeneca | 7 | $104 |
| Johnson & Johnson | 4 | $67 |
| Genentech USA, Inc. | 4 | $61 |
| Boston Scientific | 4 | $60 |
| Novo Nordisk | 2 | $43 |
| Bayer | 2 | $34 |
| Mylan Specialty L.p. | 2 | $28 |
| GSK | 2 | $25 |
| Dexcom, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Abbott | 1 | $15 |
| Circassia Inc. | 1 | $12 |
How this compares
$1,439 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 143 | $151,535 |
| EliquisApixaban | 120 | $85,255 |
| Humira PenAdalimumab | 12 | $81,738 |
| TrulicityDulaglutide | 42 | $54,897 |
| JardianceEmpagliflozin | 51 | $48,866 |
| FarxigaDapagliflozin Propanediol | 41 | $39,716 |
| OzempicSemaglutide | 21 | $28,177 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $25,923 |
| EntrestoSacubitril/Valsartan | 16 | $16,208 |
| LinzessLinaclotide | 22 | $13,351 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,250 |
| MyrbetriqMirabegron | 22 | $10,365 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,827 |
| ByettaExenatide | 11 | $9,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $256 | $210,929227 claims |
| PfizerEliquis, Paxlovid | $134 | $88,112136 claims |
| AstraZenecaFarxiga, Byetta | $104 | $49,05152 claims |
| Novo NordiskOzempic | $43 | $28,17721 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $25 | $18,43929 claims |
| NovartisEntresto | $105 | $16,20816 claims |
| AbbVieLinzess | $264 | $13,35122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Oak Harbor
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.